LeMaitre Vascular, Inc. $LMAT Shares Bought by Vanguard Group Inc.

Posted by Francis Steltz on May 12th, 2026

Vanguard Group Inc. raised its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) by 1.4% during the 4th quarter, Holdings Channel reports. The firm owned 1,622,033 shares of the medical instruments supplier’s stock after buying an additional 21,946 shares during the quarter. Vanguard Group Inc. owned approximately 0.07% of LeMaitre Vascular worth $131,547,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Royal Bank of Canada raised its position in LeMaitre Vascular by 1.5% during the first quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock worth $9,579,000 after acquiring an additional 1,735 shares during the period. AQR Capital Management LLC grew its position in shares of LeMaitre Vascular by 36.4% in the first quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock valued at $2,339,000 after purchasing an additional 7,445 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of LeMaitre Vascular by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock worth $1,013,000 after purchasing an additional 539 shares in the last quarter. Millennium Management LLC raised its position in shares of LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after purchasing an additional 115,141 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in LeMaitre Vascular by 27.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after buying an additional 55,804 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $101.64 on Tuesday. The firm has a 50-day simple moving average of $110.09 and a two-hundred day simple moving average of $94.71. The stock has a market cap of $2.32 billion, a PE ratio of 37.51, a P/E/G ratio of 3.00 and a beta of 0.60. LeMaitre Vascular, Inc. has a 1-year low of $78.35 and a 1-year high of $118.01. The company has a debt-to-equity ratio of 0.42, a current ratio of 14.32 and a quick ratio of 12.20.

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The firm had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. During the same quarter in the previous year, the business posted $0.48 earnings per share. The business’s quarterly revenue was up 11.1% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, analysts forecast that LeMaitre Vascular, Inc. will post 3 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Thursday, May 21st will be paid a dividend of $0.25 per share. The ex-dividend date is Thursday, May 21st. This represents a $1.00 annualized dividend and a dividend yield of 1.0%. LeMaitre Vascular’s dividend payout ratio is 36.90%.

Insider Buying and Selling

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,928 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the transaction, the insider directly owned 3,749 shares in the company, valued at approximately $401,143. This trade represents a 43.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO George W. Lemaitre sold 150,000 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $106.76, for a total value of $16,014,000.00. Following the sale, the chief executive officer owned 1,532,304 shares of the company’s stock, valued at $163,588,775.04. This trade represents a 8.92% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 269,891 shares of company stock worth $28,969,086. Insiders own 7.40% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the company. Freedom Capital raised LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Weiss Ratings cut shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 6th. Zacks Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a report on Monday, April 13th. Wells Fargo & Company lifted their target price on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Finally, Barrington Research boosted their target price on shares of LeMaitre Vascular from $105.00 to $120.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $112.60.

View Our Latest Stock Report on LMAT

LeMaitre Vascular News Roundup

Here are the key news stories impacting LeMaitre Vascular this week:

Positive Sentiment: LeMaitre recently reported strong quarterly results, with EPS of $0.68 topping estimates and revenue rising 11.1% year over year, which supports the company’s growth story.
Positive Sentiment: The company raised fiscal 2026 guidance, signaling confidence in continued earnings growth and helping offset some of the negative sentiment.
Neutral Sentiment: LeMaitre also declared a quarterly dividend of $0.25 per share, reinforcing its cash-generating profile but likely not a major near-term catalyst.
Negative Sentiment: CEO George W. Lemaitre sold 27,881 shares and 18,600 shares in separate transactions, adding concern that insiders may be trimming exposure after the recent run-up in the stock. Article: LeMaitre Vascular CEO George Lemaitre Sells 27,881 Shares Article: LeMaitre Vascular CEO George Lemaitre Sells 18,600 Shares of Stock
Negative Sentiment: Additional insider sales by Director Bridget A. Ross and insider Trent G. Kamke reinforce the bearish read on sentiment. Article: LeMaitre Vascular Director Bridget Ross Sells 5,044 Shares of Stock Article: LeMaitre Vascular Insider Trent Kamke Sells 2,928 Shares

LeMaitre Vascular Profile

(Free Report)

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.